SPP 635

Drug Profile

SPP 635

Alternative Names: SPP 630; SPP 635

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Speedel Experimenta
  • Class Antihypertensives
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Hypertension
  • Discontinued End-organ damage

Most Recent Events

  • 30 Jul 2010 No development reported - Phase-II for Hypertension in Germany (PO)
  • 30 Jul 2010 No development reported - Phase-II for Hypertension in Ireland (PO)
  • 09 Jul 2008 Speedel has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top